Revvity Inc. stock holds near 52-week high after strong rally

Revvity Inc. stock (ISIN US76155R1086) closed at USD 140.19 on the New York Stock Exchange on September 16, 2026, up 9.1% from the prior session and almost exactly at its 52-week high of USD 140.21, underscoring strong momentum in the shares as of mid-September 2026.

Rally brings Revvity stock to yearly peak

According to Ad-hoc-news.de, Revvity Inc. (ticker RVTY) ended the September 16, 2026 session at USD 140.19 on the New York Stock Exchange, gaining 9.1% versus the previous close and finishing essentially at its 52-week high of USD 140.21.

The same overview from Ad-hoc-news.de notes that while Revvity stock climbed 9.1% on September 16, 2026, the broad S&P 500 index fell about 0.6% in the same session, highlighting that the move in Revvity shares clearly outpaced the wider US market.

Market capitalization and trading profile

As reported by Ad-hoc-news.de, a performance snapshot based on data from Benzinga values Revvity Inc. at approximately USD 16.24 billion in market capitalization as of September 16, 2026, using a contemporaneous share price of USD 145.52 as the basis.

The same key-data section from Ad-hoc-news.de lists the 52-week high for Revvity shares at USD 140.21 and confirms that the closing price of USD 140.19 on September 16, 2026 placed the stock virtually at that level.

Fundamental backdrop and recent reporting

Investors are viewing the latest price move against the backdrop of Revvity’s recently reported financial performance, with the company positioned as a health sciences solutions and technologies provider, as described in the key-data overview on Ad-hoc-news.de.

The 2025 Annual Report referenced on SustainabilityReports provides historical context on Revvity’s performance in fiscal year 2025, but for investors in September 2026 the focus lies on the most recent interim results and guidance published by the company within the past few quarters.

While detailed quarterly figures are not laid out in the latest one-week search snapshots, the presence of the 2025 Annual Report and ongoing coverage indicates that Revvity continues to report in line with its positioning as a provider of diagnostics, life sciences tools and related technologies, with profitability and adjusted EBIT margins serving as key metrics for market assessments.

Analyst expectations and upcoming earnings date

According to the key-data summary on Ad-hoc-news.de, the next earnings date for Revvity Inc. is scheduled for October 26, 2026, giving the market a clear upcoming checkpoint at which the company will update investors on revenue growth, margins and any changes to guidance.

Forward-looking indicators on portals such as Yahoo Finance suggest that the analyst community expects Revvity shares to trade higher over a 12-month horizon, with the one-year target estimate for the stock shown at USD 141.19 on the Revvity quote page of Yahoo Finance.

For investors, this mix of a near-52-week-high share price, a mid-cap market capitalization of around USD 16.24 billion and a forward price target slightly above the recent close places Revvity among US health sciences names where expectations are for steady growth rather than dramatic re-rating, making the upcoming October 26, 2026 earnings release an important test of whether the current valuation is justified.

Valuation metrics and historical range

Data from Yahoo Finance indicate that Revvity’s market capitalization stands at roughly USD 13.98 billion on an intra-day basis within the latest available trading data, with a 52-week price range between USD 97.32 and USD 129.50 noted there based on the portal’s historical trading record; this highlights that the USD 140.19 close on September 16, 2026 reported by other sources represents a level above earlier 52-week highs captured by that dataset.

In addition, the same Yahoo Finance page shows a forward dividend of USD 0.28 per share with a yield of about 0.22%, providing Revvity shareholders with a modest income component alongside the potential for capital appreciation.

From a valuation perspective, a separate data table on Macrotrends lists Revvity with a market capitalization of USD 9.676 billion and a price-to-earnings ratio of 17.05 in a comparative overview, illustrating how the stock’s valuation metrics have evolved over time as its market cap has moved towards the mid-teens billions range in 2026.

Risk considerations and sector positioning

Revvity operates in a competitive health sciences and diagnostics landscape, where demand for testing, lab instruments and related services is influenced by macroeconomic trends, healthcare spending and research funding; the characterization of Revvity as a health sciences solutions and technologies provider on Ad-hoc-news.de places it firmly within the broader medical and life sciences tools sector.

One risk for investors is that strong share-price performance ahead of earnings can raise the bar for upcoming results: with Revvity stock trading almost exactly at its 52-week high on September 16, 2026 and having outperformed the S&P 500 by roughly 9.7 percentage points in that session, any disappointment in the next set of reported figures or guidance on October 26, 2026 could lead to volatility.

At the same time, the relatively moderate dividend yield of about 0.22% as seen on Yahoo Finance suggests that the stock’s total-return profile is driven mainly by earnings growth and multiple expansion rather than by income, making execution on strategic initiatives critical to sustaining the valuation.

Revvity stock price and as-of date

Revvity Inc. stock is referenced with a closing price of USD 140.19 on the New York Stock Exchange as of September 16, 2026, with that level standing almost exactly at the 52-week high of USD 140.21 and reflecting a single-day gain of 9.1% from the prior close; these figures give retail investors a clear snapshot of where the shares trade relative to their recent range as of the latest completed session.

More news and analyses on Revvity Inc. stock